Dilan Athauda1, Kate Maclagan2, Simon S Skene2, Martha Bajwa-Joseph2, Dawn Letchford2, Kashfia Chowdhury2, Steve Hibbert2, Natalia Budnik3, Luca Zampedri3, John Dickson4, Yazhou Li5, Iciar Aviles-Olmos1, Thomas T Warner6, Patricia Limousin1, Andrew J Lees1, Nigel H Greig5, Susan Tebbs2, Thomas Foltynie7. 1. Sobell Department of Motor Neuroscience, University College London Institute of Neurology and the National Hospital for Neurology and Neurosurgery, London, UK. 2. Comprehensive Clinical Trials Unit, University College London, London, UK. 3. Leonard Wolfson Experimental Neuroscience Centre, London, UK. 4. Institute of Nuclear Medicine, University College London Hospitals NHS Trust, London, UK. 5. Translational Gerontology Branch, Intramural Research Program, National Institute on Aging, National Institutes of Health, Baltimore, MD, USA. 6. Queen Square Brain Bank, London, UK. 7. Sobell Department of Motor Neuroscience, University College London Institute of Neurology and the National Hospital for Neurology and Neurosurgery, London, UK. Electronic address: t.foltynie@ucl.ac.uk.
Abstract
BACKGROUND:Exenatide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has neuroprotective effects in preclinical models of Parkinson's disease. We investigated whether these effects would be apparent in a clinical trial. METHODS: In this single-centre, randomised, double-blind, placebo-controlled trial, patients with moderate Parkinson's disease were randomly assigned (1:1) to receive subcutaneous injections of exenatide 2 mg or placebo once weekly for 48 weeks in addition to their regular medication, followed by a 12-week washout period. Eligible patients were aged 25-75 years, had idiopathic Parkinson's disease as measured by Queen Square Brain Bank criteria, were on dopaminergic treatment with wearing-off effects, and were at Hoehn and Yahr stage 2·5 or less when on treatment. Randomisation was by web-based randomisation with a two strata block design according to disease severity. Patients and investigators were masked to treatment allocation. The primary outcome was the adjusted difference in the Movement Disorders SocietyUnified Parkinson's Disease Rating Scale (MDS-UPDRS) motor subscale (part 3) in the practically defined off-medication state at 60 weeks. All efficacy analyses were based on a modified intention-to-treat principle, which included all patients who completed any post-randomisation follow-up assessments. The study is registered at ClinicalTrials.gov (NCT01971242) and is completed. FINDINGS:Between June 18, 2014, and March 13, 2015, 62 patients were enrolled and randomly assigned, 32 to exenatide and 30 to placebo. Our primary analysis included 31 patients in the exenatide group and 29 patients in the placebo group. At 60 weeks, off-medication scores on part 3 of the MDS-UPDRS had improved by 1·0 points (95% CI -2·6 to 0·7) in the exenatide group and worsened by 2·1 points (-0·6 to 4·8) in the placebo group, an adjusted mean difference of -3·5 points (-6·7 to -0·3; p=0·0318). Injection site reactions and gastrointestinal symptoms were common adverse events in both groups. Six serious adverse events occurred in the exenatide group and two in the placebo group, although none in either group were judged to be related to the study interventions. INTERPRETATION:Exenatide had positive effects on practically defined off-medication motor scores in Parkinson's disease, which were sustained beyond the period of exposure. Whether exenatide affects the underlying disease pathophysiology or simply induces long-lasting symptomatic effects is uncertain. Exenatide represents a major new avenue for investigation in Parkinson's disease, and effects on everyday symptoms should be examined in longer-term trials. FUNDING: Michael J Fox Foundation for Parkinson's Research.
RCT Entities:
BACKGROUND:Exenatide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has neuroprotective effects in preclinical models of Parkinson's disease. We investigated whether these effects would be apparent in a clinical trial. METHODS: In this single-centre, randomised, double-blind, placebo-controlled trial, patients with moderate Parkinson's disease were randomly assigned (1:1) to receive subcutaneous injections of exenatide 2 mg or placebo once weekly for 48 weeks in addition to their regular medication, followed by a 12-week washout period. Eligible patients were aged 25-75 years, had idiopathic Parkinson's disease as measured by Queen Square Brain Bank criteria, were on dopaminergic treatment with wearing-off effects, and were at Hoehn and Yahr stage 2·5 or less when on treatment. Randomisation was by web-based randomisation with a two strata block design according to disease severity. Patients and investigators were masked to treatment allocation. The primary outcome was the adjusted difference in the Movement Disorders Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) motor subscale (part 3) in the practically defined off-medication state at 60 weeks. All efficacy analyses were based on a modified intention-to-treat principle, which included all patients who completed any post-randomisation follow-up assessments. The study is registered at ClinicalTrials.gov (NCT01971242) and is completed. FINDINGS: Between June 18, 2014, and March 13, 2015, 62 patients were enrolled and randomly assigned, 32 to exenatide and 30 to placebo. Our primary analysis included 31 patients in the exenatide group and 29 patients in the placebo group. At 60 weeks, off-medication scores on part 3 of the MDS-UPDRS had improved by 1·0 points (95% CI -2·6 to 0·7) in the exenatide group and worsened by 2·1 points (-0·6 to 4·8) in the placebo group, an adjusted mean difference of -3·5 points (-6·7 to -0·3; p=0·0318). Injection site reactions and gastrointestinal symptoms were common adverse events in both groups. Six serious adverse events occurred in the exenatide group and two in the placebo group, although none in either group were judged to be related to the study interventions. INTERPRETATION:Exenatide had positive effects on practically defined off-medication motor scores in Parkinson's disease, which were sustained beyond the period of exposure. Whether exenatide affects the underlying disease pathophysiology or simply induces long-lasting symptomatic effects is uncertain. Exenatide represents a major new avenue for investigation in Parkinson's disease, and effects on everyday symptoms should be examined in longer-term trials. FUNDING: Michael J Fox Foundation for Parkinson's Research.
Authors: John B Buse; Michael Nauck; Thomas Forst; Wayne H-H Sheu; Sylvia K Shenouda; Cory R Heilmann; Byron J Hoogwerf; Aijun Gao; Marilyn K Boardman; Mark Fineman; Lisa Porter; Guntram Schernthaner Journal: Lancet Date: 2012-11-07 Impact factor: 79.321
Authors: Alan L Whone; Ray L Watts; A Jon Stoessl; Margaret Davis; Sven Reske; Claude Nahmias; Anthony E Lang; Olivier Rascol; Maria J Ribeiro; Philippe Remy; Werner H Poewe; Robert A Hauser; David J Brooks Journal: Ann Neurol Date: 2003-07 Impact factor: 10.422
Authors: Sonal Singh; Hsien-Yen Chang; Thomas M Richards; Jonathan P Weiner; Jeanne M Clark; Jodi B Segal Journal: JAMA Intern Med Date: 2013-04-08 Impact factor: 21.873
Authors: Yazhou Li; TracyAnn Perry; Mark S Kindy; Brandon K Harvey; David Tweedie; Harold W Holloway; Kathleen Powers; Hui Shen; Josephine M Egan; Kumar Sambamurti; Arnold Brossi; Debomoy K Lahiri; Mark P Mattson; Barry J Hoffer; Yun Wang; Nigel H Greig Journal: Proc Natl Acad Sci U S A Date: 2009-01-21 Impact factor: 11.205
Authors: Laurent Azoulay; Kristian B Filion; Robert W Platt; Matthew Dahl; Colin R Dormuth; Kristin K Clemens; Madeleine Durand; David N Juurlink; Laura E Targownik; Tanvir C Turin; J Michael Paterson; Pierre Ernst Journal: BMJ Date: 2016-02-17
Authors: T D Müller; B Finan; S R Bloom; D D'Alessio; D J Drucker; P R Flatt; A Fritsche; F Gribble; H J Grill; J F Habener; J J Holst; W Langhans; J J Meier; M A Nauck; D Perez-Tilve; A Pocai; F Reimann; D A Sandoval; T W Schwartz; R J Seeley; K Stemmer; M Tang-Christensen; S C Woods; R D DiMarchi; M H Tschöp Journal: Mol Metab Date: 2019-09-30 Impact factor: 7.422
Authors: Elliot J Glotfelty; Thomas Delgado; Luis B Tovar-Y-Romo; Yu Luo; Barry Hoffer; Lars Olson; Tobias Karlsson; Mark P Mattson; Brandon Harvey; David Tweedie; Yazhou Li; Nigel H Greig Journal: ACS Pharmacol Transl Sci Date: 2019-02-11